Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
City of Hope Medical Center
Ipsen
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Amgen
Stanford University
Nordic Nanovector
University of Pennsylvania
Brown University
ADC Therapeutics S.A.
Merck Sharp & Dohme LLC
ADC Therapeutics S.A.
Fred Hutchinson Cancer Center
Gilead Sciences
University of Washington
Merck Sharp & Dohme LLC
Boehringer Ingelheim
Dartmouth-Hitchcock Medical Center
GlaxoSmithKline
Aptevo Therapeutics
Massachusetts General Hospital
Hoffmann-La Roche
Novartis
Ohio State University Comprehensive Cancer Center